Orrick, Herrington & Sutcliffe partner E. Joshua Rosenkranz is known as “the defibrillator” for his ability to revive cases from the dead on appeal. But his latest patient may be beyond saving, based on arguments Friday before the U.S. Court of Appeals for the Federal Circuit.

Two of the three judges hearing Bio-Rad Laboratories v. 10x Genomics sounded skeptical of Rosenkranz’s arguments that 10x Genomics Inc.’s ground-breaking single-cell technology doesn’t infringe three Bio-Rad Laboratories Inc. patents, or that a Delaware jury’s award of $24 million and a 15% royalty were beyond the pale.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]